Hyperuricemia Treatment Market Size, Share, Opportunities, and Trends By Type of Disease (Gout, Chronic Kidney Diseases, Others), By Treatment Method (Uricosuric Agents, Xanthine Oxidase Inhibitors, Recombinant Uricases, Others), By End-User (Hospitals & Clinics, Specialty Diagnostic Centers, Others), And By Geography – Forecasts From 2025 To 2030
- Published : Apr 2025
- Report Code : KSI061617342
- Pages : 149
Hyperuricemia Treatment Market Size:
The Hyperuricemia Treatment Market is expected to grow at a CAGR of 6.31%, reaching a market size of US$4.329 billion in 2030 from US$3.188 billion in 2025
Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.
The hyperuricemia treatment market consists of prevention, diagnosis and treatment to address the elevated uric acid levels and their associated conditions. This market included the diagnosis of diseases caused by elevated levels of uric acid in the blood, such as gout, kidney stones, chronic kidney diseases and other related issues through various tests and diagnostic techniques used for diagnosis and monitoring the serum uric acid levels. The market also includes various treatment procedures, such as pharmacological treatments like Xanthine Oxidase Inhibitors, recombinant uricases for lowering uric production and non-pharmacological treatments, including dietary medications. This market further includes the various end-users like hospitals & clinics, specialty treatment centers and also the homecare segment.
Hyperuricemia is increasingly prevalent due to a variety of reasons, such as sedentary lifestyles contributing to poor metabolic health and weight gain that increases the risk of hyperuricemia; poor diet and dietary habits promoting diets rich in purines, such as red meat, alcohol, etc., leading to increased uric acid production among other reasons. The increasing ageing population is also a major factor driving the hyperuricemia market. The aged population is at higher risk of developing hyperuricemia due to their declining kidney function with age. Thus, during the forecast period, the hyperuricemia treatment market is anticipated to have significant growth and, thus, have significant market scope for product innovation and other related aspect for treating hyperuricemia.
What are the Hyperuricemia Treatment Market Drivers?
- Rising Prevalence of Hyperuricemia
The increasing prevalence of hyperuricemia is significantly driving the growth of the hyperuricemia market. There is an increasing prevalence of conditions like gout, kidney stones, renal disease and others like cardiovascular diseases and hypertension linked to high uric acid levels. The increase in the prevalence of hyperuricemia is due to the growing adoption of sedentary lifestyles, poor diet, purine-rich diets, obesity, and the ageing population, resulting in increased uric acid production in the body. This is evident from the data published by the National Kidney Foundation, which states that about 35.5 million U.S. adults are estimated to have kidney diseases, i.e., 1 in every 7 U.S. adults has kidney disease. Also, one in every 3 adults in the U.S. is at risk for kidney diseases. Further data by the National Health and Nutrition Examination Survey of 2017 to 2020 states that 30.4% of people aged above 70 have chronic kidney diseases which is very high when compared to 6.1% of people aged between 18-39 years having CKD, thus reflecting that ageing population is a major factor for the market to propel. Also, the data published by “The Lancet Rheumatology” states that Gout is linked with a 58% higher risk of cardiovascular disease, demonstrating that hyperuricemia is increasing the rate of other diseases like cardiovascular disease. This increase in the number of people with hyperuricemia diseases is driving the demand for diagnosis and prevention measures, thus causing the growth of hyperuricemia.
- Increasing advancements in technology for hyperuricemia diagnosis and treatment
Technological advancements are also driving the growth of the hyperuricemia market, as we are witnessing significant research and development efforts by universities and institutions focused on improving hyperuricemia diagnosis. For instance, the hyperuricemia market has seen various technological advancements in recent years, such as the development of advanced diagnostic technologies like biomarker identification, genetic testing, etc. Also, the advancement in medications like uricosuric agent drugs for lowering uric acid production has given a boost to the market. Further, technological advancements in drug delivery systems, such as using nanoparticles for targeted drug delivery, has driven the market. Thus, this growing emphasis on research and development is expected to continue in the future, further fueling the market expansion and offering new solutions for patients dealing with hyperuricemia and related conditions. For example, the ongoing development in novel therapeutic drugs to enhance the precision in targeting hyperuricemia, such as the innovative combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mammalian target of rapamycin (mTOR; ImmTOR™) inhibitors, represents a significant breakthrough in redefining gout treatment. Thus, technological development will substantially boost the hyperuricemia treatment market.
What key geographical trends are shaping the Hyperuricemia Treatment Market?
- Asia-Pacific will be the fastest-growing region during the forecast period
The hyperuricemia treatment market is segmented by geography into North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific will be the fastest-growing region. Meanwhile, North America will continue dominating the market in the coming years.
The Asia Pacific region will be the fastest-growing market during the forecast period. This growth will be due to the rising prevalence of hyperuricemia as sedentary lifestyles are ever-increasing, resulting in obesity, diabetes, and hypertension. Countries like China, India, Japan, and South Korea have an increasing prevalence of hyperuricemia. This is evident from the data by NHANES that estimates that 44.6% of the Indian population and 13.3% in China, which reached to 17.7% in 2017, are diagnosed with hyperuricemia. Also, the growing access to healthcare and increasing awareness are causing the market to grow.
Meanwhile, the North American market is estimated to hold a significant market share in the hyperuricemia market. This is driven by the advanced healthcare infrastructure, along with the ever-increasing ageing population, and modern lifestyles contribute to a sedentary way of living is causing the region to grow. The data from the U.S. National Health and Nutrition Examination Survey indicates that approximately 21% of adults, or 43 million U.S. are diagnosed with hyperuricemia. 20.6 % of Mexicans have hyperuricemia. As per data by the National Institute of Diabetes and Digestive and Kidney Diseases, about 11 per cent of men and 6 per cent of women in the United States have kidney stones at least once during their lifetime, reflecting the high prevalence of kidney-related disease. Also, CKD is most common among people ages 65 or older (34%), followed by people ages 45 to 64 (12%), and people ages 18 to 44 (6%). Reflecting, the increasing ageing population of North America will cause the market to grow.
Recent Developments in the Hyperuricemia Treatment Market:
- In December 2024, Atom Therapeutics Co. Ltd, a clinical-stage biotechnology company developing treatments for inflammatory and metabolic diseases, announced the collaboration with a subsidiary of China Medical System Holdings Ltd. for lingdolinurad (ABP-671), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia, in mainland China.
- In January 2024, Lupin Limited received approval from the U.S. FDA for its abbreviated new drug application for Febuxostat tablets, 40 mg and 80 mg. It is for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to maximally titrated doses of allopurinol. It will be produced in Lupin’s Pithampur facility in India.
Hyperuricemia Treatment Market Scope:
| Report Metric | Details |
| Hyperuricemia Treatment Market Size in 2025 | US$3.188 billion |
| Hyperuricemia Treatment Market Size in 2030 | US$4.329 billion |
| Growth Rate | CAGR of 6.31% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| List of Major Companies in the Hyperuricemia Treatment Market |
|
| Customization Scope | Free report customization with purchase |
The Hyperuricemia Treatment Market is analysed into the following segments:
- By Type of Disease
- Gout
- Chronic Kidney Diseases
- Others
- By Treatment Method
- Uricosuric agents
- Xanthine Oxidase Inhibitors
- Recombinant uricases
- Others
- By End-User
- Hospitals & Clinics
- Specialty Diagnostic Centers
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- Japan
- South Korea
- Australia
- India
- Indonesia
- Thailand
- Others
- North America
Our Best-Performing Industry Reports:
Frequently Asked Questions (FAQs)
The hyperuricemia treatment market is expected to reach a total market size of US$4.329 billion by 2030.
Hyperuricemia Treatment Market is valued at US$3.188 billion in 2025.
The hyperuricemia treatment market is expected to grow at a CAGR of 6.31% during the forecast period.
Rising gout cases, aging population, unhealthy diets, and increased R&D in novel drugs are key drivers of hyperuricemia treatment growth.
The North American region is anticipated to hold a significant share of the hyperuricemia treatment market.
Related Reports
| Report Name | Published Month | Download Sample |
|---|---|---|
| Epidermolysis Bullosa Care And Treatment Market: Forecast 2030 | Apr 2025 | |
| Retinal Disorder Treatment Market Size & Share: Report, 2023-2028 | Dec 2023 | |
| Actinic Keratosis Treatment Market Size: Report, 2024 - 2029 | Feb 2024 | |
| Hirsutism Treatment Market Size & Share: Report, 2024 - 2029 | Jan 2024 | |
| Acoustic Neuroma Treatment Market Size & Share: Report, 2024-2029 | Jan 2024 |
